UNIVERSITY OF PITTSBURGH AT PITTSBURGH
Validation of biomarkers for risk prediction and early diagnosis of Pancreatic Adenocarcinoma
Validation of biomarkers for risk prediction and early diagnosis of Pancreatic Adenocarcinoma is a funding opportunity from UNIVERSITY OF PITTSBURGH AT PITTSBURGH, up to 1263696, closing March 31, 2028.
Mar 31, 2028
(609d left)Overview
Abstract Pancreatic adenocarcinoma (PDAC), with an overall 5-year survival of 11%, is the 3rd most common cause of cancer deaths in the United States, despite accounting for only 2% of all malignancies. Only a minority of patients (~11%) are diagnosed with “localized” disease (I or IIA), which has a 5-year…